Role of human cripto-1 in tumor angiogenesis

Journal of the National Cancer Institute

Volumn 97, Issue 2, 2005, Pages 132-141

  Bianco, Caterina ^a   Strizzi, Luigi ^a   Ebert, Andreas ^c   Chang, Cindy ^a   Rehman, Aasia ^d   Normanno, Nicola ^e   Guedez, Liliana ^a   Salloum, Rita ^a   Ginsburg, Erika ^a   Sun, Youping ^a   Khan, Nadia ^a   Hirota, Morihisa ^a   Wallace Jones, Brenda ^a   Wechselberger, Christian ^f   Vonderhaar, Barbara K ^a   Tosato, Giovanna ^b   Stetler Stevenson, William G ^a   Sanicola, Michele ^g   Salomon, David S ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF MICHIGAN   (United States)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f Upper Austrian Research GmbH   (Austria)

^g BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; CRIPTO 1; EPIDERMAL GROWTH FACTOR; FIBRONECTIN; MATRIGEL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A8.G3.5; MONOCLONAL ANTIBODY B3.F6.17; PROTEIN INHIBITOR; SILICONE; TETRAZOLIUM; UNCLASSIFIED DRUG; COLLAGEN; FIBROBLAST GROWTH FACTOR 2; GROWTH PROMOTOR; LAMININ; MEMBRANE PROTEIN; PROTEOGLYCAN; RECOMBINANT PROTEIN; TDGF1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN; VASCULOTROPIN A;

ARTICLE; BREAST CANCER; CAPILLARY DENSITY; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENDOTHELIUM CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMPLANT; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULATURE; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UMBILICAL VEIN; ANIMAL; BREAST TUMOR; CELL MOTION; DRUG COMBINATION; FEMALE; IMMUNOASSAY; IMMUNOLOGY; METABOLISM; MOUSE; NUDE MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VASCULARIZATION; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN; DRUG COMBINATIONS; ENDOTHELIAL CELLS; EPIDERMAL GROWTH FACTOR; FEMALE; FIBROBLAST GROWTH FACTOR 2; GROWTH SUBSTANCES; HUMANS; IMMUNOASSAY; LAMININ; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROTEOGLYCANS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 13744255918     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji011     Document Type: Article

References (35)

1. Salomon DS, Bianco C, Ebert AD, Khan NI, De Santis M, Normanno N, et al. The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer. Endocr Relat Cancer 2000;7:199-226.
2. Wechselberger C, Ebert AD, Bianco C, Khan NI, Sun Y, Wallace-Jones B, et al. Cripto-1 enhances migration and branching morphogenesis of mouse mammary epithelial cells. Exp Cell Res 2001;266:95-105.
3. Ciardiello F, Dono R, Kim N, Persico MG, Salomon DS. Expression of cripto, a novel gene of the epidermal growth factor gene family, leads to in vitro transformation of a normal mouse mammary epithelial cell line. Cancer Res 1991;51:1051-4.
4. Ebert AD, Wechselberger C, Nees M, Clair T, Schaller G, Martinez-Lacaci I, et al. Cripto-1-induced increase in vimentin expression is associated with enhanced migration of human Caski cervical carcinoma cells. Exp Cell Res 2000;257:223-9.
5. Strizzi L, Bianco C, Normanno N, Seno M, Wecheselberger C, Wallace-Jones B, et al. Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic mice. J Cell Physiol 2004;201:266-276.
6. Shen MM, Schier AF. The EGF-CFC gene family in vertebrate development. Trends Genet 2000;16:303-9.
7. Schier AF. Nodal signaling in vertebrate development. Annu Rev Cell Dev Biol 2003;19:589-621.
8. Yeo C, Whitman M. Nodal signals to Smads through Cripto-dependent and Cripto-independent mechanisms. Mol Cell 2001;7:949-57.
9. Bianco C, Adkins HB, Wechselberger C, Seno M, Normanno N, De Luca A, et al. Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial Cells. Mol Cell Biol 2002;22: 2586-97.
10. Normanno N, De Luca A, Bianco C, Maiello MR, Carriero MV, Rehman A, et al. Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells. J Cell Physiol 2004;198:31-9.
11. Kannan S, De Santis M, Lohmeyer M, Riese DJ, 2nd, Smith GH, Hynes N, et al. Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells. J Biol Chem 1997;272:3330-5.
12. Ebert AD, Wechselberger C, Frank S, Wallace-Jones B, Seno M, Martinez-Lacaci I, et al. Cripto-1 induces phosphatidylinositol 3′-kinase-dependent phosphorylation of AKT and glycogen synthase kinase 3beta in human cervical carcinoma cells. Cancer Res 1999; 59:4502-5.
13. Bianco C, Strizzi L, Rehman A, Normanno N, Wechselberger C, Sun Y, et al. A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. Cancer Res 2003;63:1192-7.
14. Bianco C, Kannan S, De Santis M, Seno M, Tang CK, Martinez-Lacaci I, et al. Cripto-1 indirectly stimulates the tyrosine phosphorylation of erb B-4 through a novel receptor. J Biol Chem 1999;274:8624-9.
15. Bianco C, Normanno N, De Luca A, Maiello MR, Wechselberger C, Sun Y, et al. Detection and localization of Cripto-1 binding in mouse mammary epithelial cells and in the mouse mammary gland using an immunoglobulin-cripto-1 fusion protein. J Cell Physiol 2002;190:74-82.
16. Adkins HB, Bianco C, Schiffer SG, Rayhorn P, Zafari M, Cheung AE, et al. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest 2003;112:575-87.
17. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003;10:1-21.
18. De Luca A, Arra C, D'Antonio A, Casamassimi A, Losito S, Ferraro P, et al. Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts. Oncogene 2000;19:5863-71.
19. Schiffer SG, Foley S, Kaffashan A, Hronowski X, Zichittella AE, Yeo CY, et al. Fucosylation of Cripto is required for its ability to facilitate nodal signaling. J Biol Chem 2001:276:37769-78.
20. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002;62:65-74.
21. Lang I, Hoffmann C, Olip H, Pabst MA, Hahn T, Dohr G, Desoye G. Differential mitogenic responses of human macrovascular and microvascular endothelial cells to cytokines underline their phenotypic heterogeneity. Cell Prolif 2001;34:143-55.
22. Guedez L, Rivera AM, Salloum R, Miller ML, Diegmueller JJ, Bungay PM, et al. Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am J Pathol 2003;162:1431-9.
23. DeOme KB, Faulkin LJ, Jr., Bern HA, Blair PB. Development of mammary tumors from hyperplastic alveolar nodules transplanted into gland-free mammary fat pads of female C3H mice. Cancer Res 1959;19:515-20.
24. Vonderhaar BK, Ginsburg E. Intramammary delivery of hormones, growth factors, and cytokines. In Asch IA, editor. Methods in mammary gland biology and breast cancer research, New York: Kluwer Academic Press/Plenum Publisher; 2000. p. 97-9.
25. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324:1-8.
26. Ota T, Fujii M, Sugizaki T, Ishii M, Miyazawa K, Aburatani H, Miyazono K. Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells. J Cell Physiol 2002;193: 299-318.
27. Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 1997;15:2169-77.
28. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273:30336-43.
29. Mertens G, Cassiman JJ, Van den Berghe H, Vermylen J, David G. Cell surface heparan sulfate proteoglycans from human vascular endothelial cells. Core protein characterization and antithrombin III binding properties. J Biol Chem 1992;267:20435-43.
30. Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 2003;47:149-61.
31. Cheng SK, Olale F, Bennett JT, Brivanlou AH, Schier AF. EGF-CFC proteins are essential coreceptors for the TGF-beta signals Vg1 and GDF1. Genes Dev 2003;17:31-6.
32. Cheng SK, Olale F, Brivanlou AH, Schier AF. Lefty Blocks a Subset of TGFbeta Signals by Antagonizing EGF-CFC Coreceptors. PLoS Biol 2004;2:E30.
33. Harms PW, Chang C. Tomoregulin-1 (TMEFF1) inhibits nodal signaling through direct binding to the nodal coreceptor Cripto. Genes Dev 2003; 17:2624-9.
34. Gray PC, Harrison CA, Vale W. Cripto forms a complex with activin and type II activin receptors and can block activin signaling. Proc Natl Acad Sci U S A 2003:100:5193-8.
35. Watabe T, Nishihara A, Mishima K, Yamashita J, Shimizu K, Miyazawa K, et al. TGF-beta receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells. J Cell Biol 2003;163:1303-11.